Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 25, Issue 24, Pages 3726-3731Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.11.4710
Keywords
-
Categories
Funding
- NCI NIH HHS [5 P30CA14089-27L] Funding Source: Medline
Ask authors/readers for more resources
Purpose Methylenetetrahydrofolate reductase ( MTHFR) is a key enzyme regulating intracellular folate levels, which affects DNA synthesis and methylation. Two MTHFR gene polymorphisms, C677T and A1298C, are linked to altered enzyme activity. Several studies have shown these two polymorphisms to be associated with response to fluorouracil ( FU)-based treatment in advanced colon cancer patients, but data are inconsistent and contradictory. Meanwhile, epidemiologic studies demonstrated that these MTHFR polymorphisms were associated with cancer risk in a sex-specific manner. We tested the hypothesis of whether these two polymorphisms are associated with sex-specific clinical outcome in metastatic colon cancer patients treated with FU-based chemotherapy. Patients and Methods This study included 318 patients ( 177 men and 141 women) with metastatic colon cancer treated between 1992 and 2003 at the University of Southern California/Norris Comprehensive Cancer Center or Los Angeles County/ University of Southern California Medical Center. Peripheral blood samples were collected from each patient, and genomic DNA was extracted from WBCs. Two MTHFR gene polymorphisms ( C677T and A1298C) were tested by fluorogenic 5 '-nuclease assay. Results The A1298C polymorphism showed statistically significant differences in overall survival ( OS) in female, but not male, patients with metastatic colon cancer ( log-rank test, P = .038). Among females, OS was greater for patients with the A/A genotype ( n = 67; median OS, 18.4 months) compared with patients with the A/ C genotype ( n = 50; median OS, 13.9 months) or C/C genotype ( n = 10; median OS, 15.6 months). Conclusion Although preliminary, these data support the role of the A1298C polymorphism in MTHFR as prognostic marker in female patients with metastatic colon cancer. Further studies are needed to confirm these findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available